Please login to the form below

Not currently logged in
Email:
Password:

John Cooper takes over as CEO of Discovery Labs

Replaces W Thomas Amick who resigns

Specialty biotech company Discovery Labs has appointed John Cooper as its new CEO following the resignation of former chair and CEO W Thomas Amick.

Cooper will also continue to serve in his positions as president and chief financial officer while board member John Leone will take over as chair.

Amick's resignation comes after nine years serving at the Pennsylvania-based firm as a board member, six years as chair and just over two years as CEO.

During his time in charge, Discovery Labs released its first product Surfaxin (lucinactant) onto the market for use in the prevention of a respiratory distress syndrome (RDS).

Cooper will now have responsibility for ensuring the drug's commercial success, as well as steering the development of Aerosruf – an inhaled version of Surfaxin to be used with Discovery's Afectair device to deliver aerosolised medicines.

Prior to joining Discovery in 2001, he served as senior VP and chief financial officer of Chrysalis International Corporation, senior VP and chief financial officer of DNX Corporation and chief financial officer of Taratec Development Corporation.

The new chair Leone joined the Discovery board in November 2012, having previously spent time as president and CEO at Cambrex Corporation and senior VP and chief operating officer of US commercials operations at Aventis.

Joseph Mahady, who spent 30 years at Wyeth – including a period as president – has also been appointed to the Discovery board.

9th January 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics